ArticlePloS one2025
Design and validation of ultra-compact metamaterial-based biosensor for non-invasive cervical cancer diagnosis in terahertz regime.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Design, fabrication and characterization of metamaterial absorber for sensing applications.Scientific reports · 2026Article
- Machine learning-enhanced multi-band metamaterial sensor for early detection of neurological disorders.Scientific reports · 2026Article
- Article
- Article
- Machine learning-assisted optimization of a terahertz photonic metamaterial absorber for blood cancer detection.PloS one · 2026Article
- Triple-band highly sensitive terahertz metamaterial absorber for biomedical sensing applications.PloS one · 2025Article
Corrections and comments
- Retraction · 2026-02-25Compromised Peer Review · Concerns/Issues about Article · Concerns/Issues about Authorship/Affiliation · Conflict of Interest · Objections by Author(s) ·
- Retracted
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical cancer belongs to the most dangerous types of cancers posing considerable threat to women's survival. It is most often diagnosed in the advanced stages as precancerous lesions are often symptom-free and difficult to identify. Microwave imaging, especially in terahertz (THz) range, is a convenient and noninvasive cancer detection tool. It enables characterization of biological tissues and discrimination between healthy and malignant ones. This study presents a novel triple-band biosensor based on metamaterials (MTMs). By leveraging unique properties of MTMs, the proposed biosensor operates as a perfect absorber. It exploits resonant modes in the THz spectrum to achieve remarkable sensitivity. Meticulous selection of the sensor geometry and dimensions enables efficient miniaturization. Meanwhile, utilization of frequency-domain data to detect refractive index changes improves resolution of cancerous tissue identification. Extensive numerical investigations corroborate its ability to carry out reliable early-stage cervical cancer diagnosis. This includes identification of the spatial extent of the malignant tissue. Excellent electrical properties of the sensor are accompanied by its compact size, which is highly desirable for non-invasive and portable applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.